21st week of 2012 patent applcation highlights part 51 |
Patent application number | Title | Published |
20120129714 | QUANTITATIVE MULTIPLEXED IDENTIFICATION OF NUCLEIC ACID TARGETS - Methods and systems for detecting a target nucleic acid using the quantitative capabilities of real-time nucleic acid amplification systems and the multiplexing capabilities of hybridization systems, comprising: identifying a conservative sequence and a distinctive sequence within each target nucleic acid sequence; simultaneously amplifying the conservative region and the distinctive region; monitoring the amplification of the conservative region in real-time; identifying the distinctive region amplicon via multiplexed identification; and performing quantitative multiplexing analysis of the target by combining the real-time monitoring information with the multiplexed identification of the target nucleic acid. | 2012-05-24 |
20120129715 | GB1 PEPTIDIC LIBRARIES AND METHODS OF SCREENING THE SAME - GB1 peptidic libraries and methods of screening the same for specific binding to a target protein are provided. Libraries of polynucleotides that encode GB1 peptidic compounds are provided. These libraries find use in a variety of applications in which specific binding to target molecules, e.g., target proteins is desired. Also provided are methods of screening the libraries for binding to a target. | 2012-05-24 |
20120129716 | USE OF MICROFLUIDIC SYSTEMS IN THE DETECTION OF TARGET ANALYTES USING MICROSPHERE ARRAYS - The invention relates generally to methods and apparatus for conducting analyses, particularly microfluidic devices for the detection of target analytes. | 2012-05-24 |
20120129717 | Collection and Methods For Its Use - The present disclosure enables collections of variable heavy chain and variable light chain pairs comprising, in part, germline protein sequences that are pre-selected for functional properties relevant to developability, wherein the collections may be used to select against any antigen using, for example, phage display. | 2012-05-24 |
20120129718 | Qualitative/Quantitative Detection of Fungal Species - A method based on species-specific molecular markers applied to a multiplex platform system is provided that permits, in a one-time assay, the qualitative and quantitative screening of multi-species populations in several dozens of environmental samples, tested in parallel, with low cost and rapid turn-around. The method identifies a specific portion of DNA, shared amongst a variety of important mold species, but with sufficient sequence differences that allow for unique identifications. Two pairs of primers, which are capable of amplifying this region across at least 38 different mold species, have been identified. Also short oligonucleotide probes have been designed specifically for each species to detect their presence and concentration in mixed species environmental samples. The method of detection of the invention can be practiced using conventional PCR reactions, followed by nucleotide hybridization assays and quantization of the hybridized biotinylated amplicons in a multiplex liquid array system. | 2012-05-24 |
20120129719 | Mechanically induced trapping of molecular interactions - The invention provides devices and methods for surface patterning the substrate of a microfluidic device, and for detection and analysis of interactions between molecules by mechanically trapping a molecular complex while substantially expelling solvent and unbound solute molecules. Examples of molecular complexes include protein-protein complexes and protein-nucleic acid complexes. | 2012-05-24 |
20120129720 | APTAMER THAT RECOGNIZES PEPTIDE - An aptamer capable of binding to a histidine peptide is provided. A nucleic acid used as the aptamer capable of binding to a histidine peptide is any of the following nucleic acids (a) to (d): (a) a nucleic acid having a base sequence represented by SEQ ID NO: 17: GGUN | 2012-05-24 |
20120129722 | METHOD FOR SCREENING NEW DRUG CANDIDATE INHIBITING TARGET PROTEIN-PROTEIN INTERACTION FOR DEVELOPMENT OF FIRST-IN-CLASS DRUG - The present invention relates to a method for screening a substance inhibiting protein-protein interactions, and more particularly to a method for screening a substance inhibiting protein-protein interactions, the method comprising using a protein chip having immobilized thereon spots comprising a mixture of a sol-gel material and a protein. According to the invention, a protein chip can be easily manufactured in a 96-well plate using a sol-gel material, whereby an inhibitor that inhibits protein-protein interactions can be easily screened from a library of natural substances. | 2012-05-24 |
20120129723 | SYSTEM AND METHOD FOR CARRYING OUT MULTIPLE BINDING REACTIONS IN AN ARRAY FORMAT - Provided is a method for determining one or more kinetic parameters of binding between a first binding member and a second binding member. The method includes adsorbing the first binding member to a surface at a plurality of microspots. The second binding member is then presented to the first binding member at each of the microspots, there being a plurality of combinations of first binding member surface density and second binding member concentration among the plurality of microspots. Data indicative of a binding reaction between the first of microspots are then obtained and analyzed so as to obtain one or more kinetic parameters of the binding between the first and second binding members. Also provided is a system for carrying out the method. A method for localizing a molecular species at microspots on a surface, and a probe array produced by the method are also provided. | 2012-05-24 |
20120129724 | MARKER AND REAGENT FOR DETECTION OF HUMAN IL-17-PRODUCING HELPER T CELLS, AND METHOD FOR DETECTION OF HUMAN IL-17-PRODUCING HELPER T CELLS - The present invention relates to a marker allowing specific detection of human IL-17-producing helper T-cells (human Th17 cells), a method for specifically detecting human Th17 cells and a reagent for detecting human Th17 cells. | 2012-05-24 |
20120129725 | NUCLEIC ACID NANO-BIOSENSORS - There is provided nanobiosensors and more particularly sensors comprising one or more aptamers or other functional nucleic acids adapted for signalling incorporated within a nanoparticle comprising polyacrylamide or other suitable polymer. Moreover, there is provided a novel DNA aptamer, which selectively binds to ATP. There is also provided a novel nanobiosensor for monitoring ATP concentrations in samples, including biological samples; this new approach may be used to monitor kinase activity in a given sample. | 2012-05-24 |
20120129726 | SUBCELLULAR IN VIVO TIME-LAPSE IMAGING AND SURGERY OF C. ELEGANS IN STANDARD MULTIWELL PLATES - High-content time-lapse assays on whole animals require their repeated immobilization for high-resolution imaging and manipulation. Here, we present a simple, rapid, and minimally invasive method for repeatedly immobilizing and imaging | 2012-05-24 |
20120129727 | EFFICIENT AND EFFECTIVE SUPPLEMENT SCREENING FOR THE DEVELOPMENT OF CHEMICALLY DEFINED MEDIA IN CELL CULTURE - The present invention relates to methods of selecting and developing a chemically defined media (“CDM”) for use in the manufacture of biological products. In particular, the present invention is directed to screening methods to determine cell culture technique media supplement blends with enhanced performance characteristics. The present invention is also directed to identifying CDM supplement blends that demonstrate significant increases in harvest titer and/or viable cell density. | 2012-05-24 |
20120129728 | Methods and Apparatus for Measuring Analytes Using Large Scale FET Arrays - Methods and apparatus relating to very large scale FET arrays for analyte measurements. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. In one example, chemFET arrays facilitate DNA sequencing techniques based on monitoring changes in hydrogen ion concentration (pH), changes in other analyte concentration, and/or binding events associated with chemical processes relating to DNA synthesis. | 2012-05-24 |
20120129729 | Method for Determining the Methylation Pattern of a Polynucleic Acid - Particular aspects relate to a method for determining the methylation pattern of a polynucleic acid, comprising: a) preparing a solution comprising a mixture of fragments of the polynucleic acid; b) coupling the fragments with a substance being detectable with a detection method; c) contacting a solution comprising the fragments of b) with a DNA microarray having a plurality of different immobilized oligonucleotides, each comprising at least one methylation site, at respectively assigned different locations thereon, the contacting under conditions affording hybridization of fragments with correlated immobilized oligonucleotides under defined stringency, and wherein the immobilized oligonucleotides have a length of less than 200 bases; d) optionally performing a washing step; and e) detecting, using the physical detection method, such immobilized nucleic acids to which solution fragments are hybridized and/or to which solution fragments are not hybridized. | 2012-05-24 |
20120129730 | GENERATION OF COMPOUND LIBRARIES UTILIZING MOLECULAR IMPRINTS INCLUDING A DOUBLE OR ANTI-IDIOTYPIC APPROACH - The present invention relates to a method of producing new chemical entities comprising the steps of: (i) taking a chemical entity as the template to prepare a molecularly imprinted polymer (MIP), (ii) removing the template from the MIP, (iii) using the specific binding sites of the MIP to direct, or facilitate, the syntheses of new chemical entities for the generation of compound libraries using molecularly imprinted polymers, and to a use of such compound libraries. | 2012-05-24 |
20120129731 | Design and construction of diverse synthetic peptide and polypeptide libraries - The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for generating sequence diversity by directed multisyntheses oligonucleotide synthesis. The present methods enable the reduction of large complex annotated databases to simpler datasets of related sequences, based upon relevant single or multiple key parameters that can be individually directly defined. The methods further enable the creation of diverse libraries based on this approach, using multisynthetic collections of discrete and degenerate oligonucleotides to capture the diverse collection of sequences, or portions thereof. | 2012-05-24 |
20120129732 | Methods and Apparatus for Measuring Analytes Using Large Scale FET Arrays - Methods and apparatus relating to very large scale FET arrays for analyte measurements. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes. In one example, chemFET arrays facilitate DNA sequencing techniques based on monitoring changes in hydrogen ion concentration (pH), changes in other analyte concentration, and/or binding events associated with chemical processes relating to DNA synthesis. | 2012-05-24 |
20120129733 | SYSTEMS AND METHODS FOR PROCESSING GLYCEROL - Systems and methods for processing glycerol into one or more useful products are provided. The method can include decreasing a pH of a mixture comprising glycerol and fatty acids to produce an emulsion comprising a glycerol-rich portion and a fatty acids-rich portion. At least a portion of the glycerol-rich portion can be reacted with at least one of an oxidant and a catalyst at conditions sufficient to produce a reacted product comprising glyceric acid, oxalic acid, glycolic acid, formic acid, or any combination thereof. | 2012-05-24 |
20120129734 | USE OF HYDROPHOBICALLY ASSOCIATED COPOLYMER AS AN ADDITIVE IN SPECIFIC OILFIELD APPLICATIONS - What is proposed is the use of a water-soluble hydrophobically associating copolymer as an additive in the development, exploitation and completion of underground mineral oil and natural gas deposits and in deep drillings, wherein the copolymer comprises (a) at least one monoethylenically unsaturated monomer (a) selected from | 2012-05-24 |
20120129735 | NON-AQUEOUS DRILLING ADDITIVE USEFUL TO PRODUCE A FLAT TEMPERATURE-RHEOLOGY PROFILE - A method of providing a substantially constant equivalent circulating density of a drilling fluid over a temperature range of about 120° F. to about 40° F. includes adding a drilling fluid additive to the drilling fluid, wherein the drilling fluid additive includes the reaction product of a carboxylic acid with a single carboxylic moiety; and a polyamine having at least two primary amino functionalities and optionally at least one secondary amino functionality. | 2012-05-24 |
20120129736 | HIGHLY OXIDIZED GRAPHENE OXIDE AND METHODS FOR PRODUCTION THEREOF - A highly oxidized form of graphene oxide and methods for production thereof are described in various embodiments of the present disclosure. In general, the methods include mixing a graphite source with a solution containing at least one oxidant and at least one protecting agent and then oxidizing the graphite source with the at least one oxidant in the presence of the at least one protecting agent to form the graphene oxide. Graphene oxide synthesized by the presently described methods is of a high structural quality that is more oxidized and maintains a higher proportion of aromatic rings and aromatic domains than does graphene oxide prepared in the absence of at least one protecting agent. Methods for reduction of graphene oxide into chemically converted graphene are also disclosed herein. The chemically converted graphene of the present disclosure is significantly more electrically conductive than is chemically converted graphene prepared from other sources of graphene oxide. | 2012-05-24 |
20120129737 | HETEROGENEOUS PROPPANT PLACEMENT IN A FRACTURE WITH REMOVABLE CHANNELANT FILL - A method of heterogeneous proppant placement in a subterranean fracture is disclosed. The method comprises injecting well treatment fluid including proppant and a channelant through a wellbore into the fracture, heterogeneously placing the proppant in the fracture in a plurality of proppant clusters or islands spaced apart by the channelant, and removing the channelant filler material to form open channels around the pillars for fluid flow from the formation through the fracture toward the wellbore. The proppant and channelant can be segregated within the well treatment fluid, or segregated during placement in the fracture. The channelant can be dissolvable particles, initially acting as a filler material during placement of the proppant, and later dissolving to leave the flow channels between the proppant pillars. The well treatment fluid can include fibers to provide reinforcement and consolidation of the proppant and/or to inhibit settling of the proppant in the treatment fluid. | 2012-05-24 |
20120129738 | OIL FIELD TREATMENT FLUIDS COMPRISING ZWITTERIONIC BETAINE-GROUP-CONTAINING POLYMERS - The present disclosure is directed to a method comprising: mixing (i) a zwitterionic polymer prepared by inverse emulsion polymerization of at least one monomer A | 2012-05-24 |
20120129739 | WATER-SOLUBLE, HYDROPHOBIC ASSOCIATING COPOLYMERS - Water-soluble, hydrophobically associating copolymer comprising a monoethylenically unsaturated, water-soluble, surface-active monomer (a), and a monoethylenically unsaturated, hydrophilic monomer (b) different from monomer (a). The copolymer is prepared in the presence of a nonpolymerizable surfactant and has marked thickening properties in aqueous systems. | 2012-05-24 |
20120129740 | SELF-LUBRICATING COATING AND METHOD FOR PRODUCING A SELF-LUBRICATING COATING - The invention relates to a coating ( | 2012-05-24 |
20120129741 | LUBRICATING COMPOSITION - The present invention provides a lubricating composition for use in the crankcase of an engine comprising a base oil and one or more additives, wherein the base oil comprises a Fischer-Tropsch derived base oil and wherein the lubricating composition has a kinematic viscosity at 100 C (according to ASTM D 445} of below 5.6 cSt and a Noack volatility (according to ASTM D 5800) of below 15 wt. %. | 2012-05-24 |
20120129742 | NOVEL ADDITIVES FOR TRANSMISSION OILS - The subject of the disclosure concerns microcapsules including a core containing one or more alkali metal borates, optionally hydrated, dispersed in one or more lubricating base oils of mineral, synthetic or natural origin, and a polymer shell. Another subject of the disclosure is a lubricating oil including microcapsules. A further subject of the disclosure is the use of microcapsules according to the disclosure as anti-wear and/or extreme pressure additive for lubricant compositions. A further subject of the disclosure is a method for preparing microcapsules by interface polymerization. | 2012-05-24 |
20120129743 | LUBRICATING COMPOSITION CONTAINING FRICTION MODIFIER BLEND - Disclosed are friction modifier compositions and a method of lubricating an internal combustion engine, comprising supplying to said engine an oil of lubricating viscosity and from 0.25 to 5 weight percent based upon the total mass of the lubricating oil composition of a friction modifier composition containing:
| 2012-05-24 |
20120129744 | LUBRICATING COMPOSITION CONTAINING 1,3-DIOXOLANE-4-METHANOL COMPOUNDS AS ANTIWEAR ADDITIVES - Disclosed are lubricating oil compositions comprising a major amount of an oil of lubricating viscosity; and from 0.05 to 10 weight % based upon the total lubricating oil composition of a 1,3-dioxolane-4-methanol compound of the formula I: | 2012-05-24 |
20120129745 | LUBRICANT FOR PERCUSSION EQUIPMENT - This invention discloses a lubricant suitable for use in percussion equipment. The lubricant comprises a base oil selected from the group consisting of Group I or Group II, blended in a synergistic amount with a gear oil package and a friction modifier. The lubricant exhibits superior wear and superior extreme pressure properties due to the synergistic effect of the gear oil package and the friction modifier. In a preferred embodiment, the gear oil package comprises a polyalkyl methacrylate polymer, and the friction modifier comprises a synthetic ester. | 2012-05-24 |
20120129746 | MODIFIED VEGETABLE OIL LUBRICANTS - Lubricants based on renewable feedstocks and methods of making them. | 2012-05-24 |
20120129747 | POST ION IMPLANT STRIPPER FOR ADVANCED SEMICONDUCTOR APPLICATION - The present invention relates to a substantially water-free photoresist stripping composition. Particularly, the present invention relates to a substantially water-free photoresist stripping composition useful in removing the photoresist after ion-implant process, comprising: (a) an amine, (b) an organic solvent A, and (c) a co-solvent, wherein the composition is substantially water-free (<3 wt % H | 2012-05-24 |
20120129748 | DOSAGE FORM DETERGENT PRODUCTS - A method of producing a dosage form detergent product, comprises the steps of: (a) producing an open-mouthed pouch by forming a water-soluble, synthetic plastics film into a mould cavity defining said pouch, (b) introducing a particulate first detergent composition into the pouch, (c) forming a recess in the upper surface of the particulate first detergent composition, (d) introducing into said recess a pre-formed, shape-retaining second detergent component with an at least substantially planar face positioned to be exposed from the particulate first detergent component, and (e) sealing a water-soluble film over the mouth of the pouch and against said exposed face of the pre-formed detergent product. | 2012-05-24 |
20120129749 | COPOLYMERS COMPRISING CARBOXYLIC ACID GROUPS, SULFO GROUPS AND POLYALKYLENE OXIDE GROUPS AS A SCALE-INHIBITING ADDITIVE TO WASHING AND CLEANING PRODUCTS - The invention relates to copolymers which comprise, in copolymerized form,
| 2012-05-24 |
20120129750 | Copolymers Comprising Carboxylic Acid Groups, Sulfo Groups and Polyalkylene Oxide Groups as a Scale-Inhibiting Additive to Washing and Cleaning Products - The invention relates to copolymers which comprise, in copolymerized form,
| 2012-05-24 |
20120129751 | BIS-AZO COLORANTS FOR USE AS BLUING AGENTS - Bis-azo colorants for use as bluing agents, laundry care compositions including bis-azo colorants that may serve as bluing agents, processes for making such bluing agents and laundry care compositions and methods of using the same. The bluing agents are generally include at least two components: at least one chromophore component and at least one polymeric component. These bluing agents are advantageous in providing a whitening effect to fabrics, while not building up over time and causing undesirable blue discoloration to the treated fabrics. | 2012-05-24 |
20120129752 | LOW BUILT DETERGENT COMPOSITION COMPRISING BLUING AGENT - A solid laundry detergent composition having: (a) detersive surfactant; (b) bluing agent; and (c) from 0 wt % to 10 wt % zeolite builder; (d) from 0 wt % to 10 wt % phosphate builder; and (e) optionally, one or more additional laundry detergent ingredients. | 2012-05-24 |
20120129753 | DETERGENT COMPOSITION COMPRISING BLUING AGENT AND CLAY SOIL REMOVAL / ANTI-REDEPOSITION AGENT - A laundry detergent composition having: (a) detersive surfactant; (b) bluing agent, and (c) a clay and soil removal/anti-redeposition agent; and (d) optionally, one or more additional laundry detergent ingredients. | 2012-05-24 |
20120129754 | Afterclearing Agents - A composition comprising (a) a homo- or copolymer obtainable by polymerisation of at least one ethylenically un-saturated nitrogen-containing heterocyclic compound and (b) a polyethyleneimine, is suitable for afterclearing a printed or dyed textile material, in particular cotton fibres dyed or printed with reactive dyes. | 2012-05-24 |
20120129755 | LIQUID CLEANING COMPOSITION - The present invention relates to a liquid cleaning composition comprising a peroxygen bleach, a sulfonated anionic surfactant and an amphoteric/zwitterionic surfactant where the sulfonated anionic surfactant and the amphoteric/zwitterionic surfactants are in a ratio of from 0.1:1 to 13:1. The combination of the sulfonated anionic surfactant and the amphoteric/zwitterionic surfactants provides for high viscosities and improved cleaning performance. | 2012-05-24 |
20120129756 | Dilutable cleaning compositions and methods for use - An environmentally-friendly, low VOC cleaning composition for industrial and consumer applications comprising (a) a blend of dibasic esters, (b) one or more nonionic surfactants (c) and, optionally, (d) water or a solvent. The dibasic esters are be derived from a blend of adipic, glutaric, and succinic diacids, and, in one particular embodiment, the blend comprises dialkyl adipate, dialkyl methylglutarate and dialkyl ethylsuccinate, wherein the alkyl groups individually comprise a C | 2012-05-24 |
20120129757 | COMPOSITIONS AND METHODS FOR PROMOTING VASCULAR BARRIER FUNCTION AND TREATING PULONARY FIBROSIS - Active agents and compositions that promote barrier function or that inhibit permeability of the vascular endothelium associated with pulmonary inflammation are described. | 2012-05-24 |
20120129758 | MUSCLE FUNCTION ENHANCING PEPTIDE - The present invention relates to a peptide comprising a muscle function enhancing amino acid sequence which is derived from the S100 calcium binding protein family. Furthermore, the present invention provides said peptide for medical use, in particular, for treating or preventing disorders associated with muscular malfunction, such as skeletal muscle or cardiac muscle disorders. The present invention also provides a pharmaceutical composition comprising said peptide and a method for treating or preventing disorders associated with muscular malfunction using said peptide or said pharmaceutical composition. | 2012-05-24 |
20120129759 | PROTEIN SURFACE REMODELING - Aggregation is a major cause of the misbehavior of proteins. A system for modifying a protein to create a more stable variant is provided. The method involves identifying non-conserved hydrophobic amino acid residues on the surface of a protein, suitable for mutating to more hydrophilic residues (e.g., charged amino acids). Any number of residues on the surface may be changed to create a variant that is more soluble, resistant to aggregation, has a greater ability to re-fold, and/or is more stable under a variety of conditions. The invention also provides GFP, streptavidin, and GST variants with an increased theoretical net charge created by the inventive technology. Kits are also provided for carrying out such modifications on any protein of interest. | 2012-05-24 |
20120129760 | Modified peptides with antiviral properties and methods for obtaining them - This invention may be used in human and veterinary medicine for the creation of a drug that is effective perorally in the treatment of many viral infections, such as influenza, herpes, and cytomegalovirus. | 2012-05-24 |
20120129761 | PREPARATION OF BONE CEMENT COMPOSITIONS - A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising
| 2012-05-24 |
20120129762 | MOTILIN-LIKE PEPTIDE COMPOUND HAVING TRANSMUCOSAL ABSORBABILITY IMPARTED THERETO - The present invention aims at providing motilin-like peptide compounds that maintain the gastrointestinal motility stimulating activity of native motilin and which are adapted to have higher absorbability upon transmucosal administration. | 2012-05-24 |
20120129763 | NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS - Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of a glycopeptide (Compound A, Compound B, Compound H or Compound C) or monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Key reaction is the treatment of properly protected intermediate compound with isocyanate or carrying a Hofmann degradation of the primary amide of the 3 | 2012-05-24 |
20120129764 | INFLUENZA A AND B VIRUS REPLICATION-INHIBITING PEPTIDES - A synthesized or isolated influenza virus replication-inhibiting peptide that competitively inhibits protein-protein interaction of the PA and PB1 of both influenza Virus Types A and B and novel in vitro binding screen to identify peptides with antiviral activity against influenza viruses of both type A and B is disclosed. In addition to the well-known pandemic influenza A viruses (such as the 1918 “Spanish” flu or H5N1), both type A and B viruses contribute greatly to the annual recurring epidemics that cause the vast majority of human cases and medical cost. Surprisingly, it was found that the novel virus replication-inhibiting, are able to inhibit protein-protein interaction of the PA and PB1 subunits of the heterotrimeric viral RNA polymerase complex of both influenza virus types A and B. The viral polymerase sub-unit interaction domain turned out as an effective target for the new antivirals, as correct assembly of the three viral polymerase subunits PB1, PB2 and PA is required for viral RNA synthesis and infectivity. | 2012-05-24 |
20120129765 | NOVEL SPECIFIC HCV NS3 PROTEASE INHIBITORS - The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts. | 2012-05-24 |
20120129766 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS - The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions. | 2012-05-24 |
20120129767 | USE OF A GHRELIN AGONIST TO IMPROVE THE CATABOLIC EFFECTS OF GLUCOCORTICOID TREATMENT - A method and pharmaceutical composition for inhibiting the effect of glucocorticoids, particularly dexamethasone, which suppress growth hormone secretion, by administering ghrelin or a ghrelin analogue, for example, [Aib | 2012-05-24 |
20120129768 | GLP-1 ANALOGUES AND THEIR PHARMACEUTICAL SALTS AND USES - This invention discloses GLP-1 analogues and their pharmaceutical salts, wherein the GLP-1 analogue comprises an amino acid sequence of general formula (I), wherein Lys represents a modified lysine with a lipophilic acid. The GLP-1 analogues provided by this invention have the function of human GLP-1, and a longer half-life in vivo compared with the human GLP-1. Uses of such compounds and compositions include treating non-insulin-dependent diabetes, insulin-dependent diabetes, and obesity. | 2012-05-24 |
20120129769 | ORALLY ADMINISTERABLE PHARMACEUTICAL PREPARATION CONTAINING INSULIN - The subject of the invention is an orally administerable pharmaceutical preparation containing a combination of biotechnologically produced human recombinant insulin and/or modified insulin or an analogue and/or derivative thereof, a protease inhibitor and a high molecular weight (natural) protein. The invention relates to a method for the production of the pharmaceutical preparation as well. The subject of the invention also covers the use of the pharmaceutical preparation and a method for the treatment of diabetes in mammals. | 2012-05-24 |
20120129770 | NOVEL POLYNUCLEOTIDE MOLECULES FOR ENHANCED GENE EXPRESSION - Disclosed herein is an isolated polynucleotide molecule encoding protein such as erythropoietin or structural variants, comprising an expression regulating nucleotide sequence operatively linked to a nucleotide sequence(s) encoding said proteins. The said expression regulatory region comprises of Exon A and at least proximal region of Intron A of Major Immediate Early Region of human Cytomegalovirus or its functional variants which when transfected into host cells results in many fold increase in expression of the protein. | 2012-05-24 |
20120129771 | PEPTIDES AND RELATED MOLECULES THAT MODULATE NERVE GROWTH FACTOR ACTIVITY - The present invention relates to certain biologically active peptides and polypeptides which can be used as therapeutics or prophylactics against diseases or disorders linked to NGF as the causative agent. In one aspect of the present invention, pharmacologically active polypeptides comprising peptides linked to one or more Fc domains are provided. | 2012-05-24 |
20120129772 | SOLUBLE IGF RECEPTORS AS ANTI-ANGIOGENIC AGENTS - There is disclosed a method of inhibiting angiogenesis in a patient having an angiogenic associated disorder comprising administering to said patient a therapeutically effective amount of a soluble IGF-IR protein. The use of such soluble IGF-IR protein for inhibiting angiogenesis in a patient is also disclosed. | 2012-05-24 |
20120129773 | METHODS OF TREATING AUTISM AND AUTISM SPECTRUM DISORDERS - The present invention relates to methods of treating a subject diagnosed with autism or an autism spectrum disorder, lowering the level of mercury in a subject determined to contain a high level of mercury, methods of lowering the level of mercury in a child diagnosed with autism, lowering the level of at least one androgen in a subject diagnosed with autism, lowering the level of mercury and the level of at least one androgen in a subject diagnosed with autism and methods of assessing the risk of whether a child is susceptible of developing autism. | 2012-05-24 |
20120129774 | KININ B1 RECEPTOR PEPTIDE AGONISTS AND USES THEREOF - The present invention provides for novel kinin B | 2012-05-24 |
20120129775 | ANTIANGIOGENIC SMALL MOLECULES AND METHODS OF USE - Methods of inhibiting undesired angiogenesis are provided, which methods include administering to a subject a therapeutically effective amount of at least one of the compounds described herein, or a pharmaceutically acceptable salt thereof. | 2012-05-24 |
20120129776 | Bioactive peptides and method of using same - Disclosed are peptide ligands for G-protein coupled receptors that are useful for treating disorders associated with G-protein coupled receptor activation. | 2012-05-24 |
20120129777 | Methods for Treating Bleeding Disorders Using Sulfated Polysaccharides - Methods for treating bleeding disorders using non-anticoagulant sulfated polysaccharides (NASPs) as procoagulants are disclosed. NASPs can be administered as single agents, or in combination with one another, or, with other medications (such as factors VII, VIII and IX) to promote hemostasis. In particular, the use of NASPs in treatment of bleeding disorders, including congenital coagulation disorders, acquired coagulation disorders, and trauma induced hemorrhagic conditions is described. | 2012-05-24 |
20120129778 | LIGAND THAT BIND TGF-BETA RECEPTOR RII - The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. The disclosure also provides a polypeptide, ligand or pharmaceutical composition for treating a disease associated with TGFbeta signaling and a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis, liver fibrosis, including cirrhosis and chronic hepatitis, rheumatoid arthritis, ocular disorders, or fibrosis of the skin, including keloid of skin, and kidney such as nephritis, kidney fibrosis and nephrosclerosis, and a vascular condition, such as restenosis. | 2012-05-24 |
20120129779 | TUBULYSINE DERIVATIVES - The present invention relates to novel cytotoxic molecules and their use for the treatment of cancer and other diseases. | 2012-05-24 |
20120129780 | LACTOFERRIN AND BRAIN HEALTH AND PROTECTION IN ADULTS - The present invention relates generally to the field of brain health, brain protection, maintenance of cognitive function, prevention of cognitive decline and cognitive disorders. Neuronal cells in the brain can be protected. Also cognitive performance can be increased. | 2012-05-24 |
20120129781 | COMPOSITION COMPRISING ALPHA-LIPOIC ACID AND CARNOSINE FOR TREATING THE PHANTOM LIMB SYNDROME - The present invention relates to a composition comprising an effective amount of α-lipoic and carnosine, or pharmaceutically acceptable derivatives thereof for treating the phantom limb syndrome. The present invention also relates to the use of such a composition for treating the phantom limb syndrome. | 2012-05-24 |
20120129782 | Inhibition of ApoE Cleavage Activity in the Treatment of ApoE-Related Disorders - The present invention provides methods for treating apoE-related disorders. The methods generally involve administering an effective amount of an agent that inhibits activity of an enzyme that cleaves apoE. | 2012-05-24 |
20120129783 | Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders - The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens. | 2012-05-24 |
20120129784 | Oligopeptides And Cosmetic Compositions Containing The Oligopeptides - Oligopeptides according to formula (I) and/or (II), R | 2012-05-24 |
20120129785 | COMPANION ANIMAL NUTRITION SYSTEM - The invention encompasses a nutrition system for a companion animal that includes a plurality of pet food packets, wherein an amount of pet food corresponding to a single meal for a companion animal may be selected and wherein the amount of pet food is formulated to alleviate or manage a disorder in a companion animal. In various embodiments, the pet food packets include the nutritional requirements for a companion animal (e.g., protein, fiber, fat) as well as one or more ingredients that alleviate or manage a disorder in a companion animal. | 2012-05-24 |
20120129786 | NOVEL COMPOSITION - The present invention relates to compositions comprising a peptide with 2-12 amino acids substituted with a lipophilic moiety and a water soluble salt of an alkali, earth alkaline metal or transition metal. Furthermore, the invention relates to a container comprising such compositions. Additionally, the invention relates to the use of a water soluble salt of an alkali, earth alkaline metal or transition metal for reducing the adhesion of a peptide with 2-12 amino acids substituted with a lipophilic moiety to a surface. | 2012-05-24 |
20120129787 | Modified oligopeptides with anticancer properties and methods of obtaining them - This invention may be used in human and veterinary medicine for the creation of a drug that is effective perorally in the treatment of oncological illnesses. | 2012-05-24 |
20120129788 | PHOSPHODIESTERASE 4D7 AS MARKER FOR MALIGNANT, HORMONE-SENSITIVE PROSTATE CANCER - The present invention relates to phosphodiesterase 4D7 (PDE4D7) for use as a marker for malignant, hormone-sensitive prostate cancer, wherein the expression of the marker is increased when comparing the expression in malignant, hormone-sensitive prostate cancer tissue, to the expression in normal tissue or benign prostate tumor tissue, and the use of PDE4D7 as a diagnostic marker for malignant, hormone-sensitive prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating malignant, hormone-sensitive prostate cancer, a corresponding detection method, a method allowing to discriminate between a benign and malignant hormone-sensitive prostate cancer and a method of data acquisition, as well as corresponding immunoassays. The present invention also relates to a method of identifying an individual for eligibility for malignant, hormone-sensitive prostate cancer as well as an immunoassay for stratifying an individual with such prostate cancer. The present invention further envisages pharmaceutical compositions and their use for the treatment of malignant, hormone-sensitive prostate cancer. | 2012-05-24 |
20120129789 | COMPOSITIONS AND METHODS FOR HAIR GROWTH - The present invention is directed to compositions and methods comprising the use of bimatoprost and cyclosporine, used concurrently and in combination, to grow hair and for the treatment of all types of hair loss conditions such as but not limited to alopecia areata. The present invention is also directed to compositions containing bimatoprost and cyclosporine A to grow hair on the scalp and other areas of the body and methods of administration of the compositions. | 2012-05-24 |
20120129790 | METHODS OF USE OF EPSILON INHIBITOR COMPOUNDS FOR THE ATTENUATION OF PAIN - The disclosure herein relates to modified εPKC inhibitory peptides, methods of generating such peptides, and method for using εPKC inhibitory peptides for the treatment of pain. | 2012-05-24 |
20120129792 | AGENT FOR ELIMINATING MULTIDRUG RESISTANCE - The invention belongs to medicine, namely to pharmacology, and may be used to overcome multiple drug resistance in oncological and infectious patients undergoing long-term chemotherapy. Essence of the invention: proposed herein as a therapeutic agent intended to overcome multiple drug resistance is a hexapeptide with the following structural formula: lysyl-histidyl-glycyl-lysyl-histidyl-glycine. | 2012-05-24 |
20120129793 | Antimicrobial Polyether and Polyol Compounds - The present application describes compounds of Formula I and Formula IA and as disclosed herein, that are useful as anti-microbial agents, including as antibacterial, disinfectant, antifungal, germicidal or antiviral agents. | 2012-05-24 |
20120129794 | APPARATI, METHODS, AND COMPOSITIONS FOR UNIVERSAL MICROBIAL DIAGNOSIS, DETECTION, QUANTIFICATION, AND SPECIMEN-TARGETED THERAPY - Microbial ecology of a specimen is evaluated using an approach (Level I) that utilizes nucleic acid amplification with specific gene primers that will identify panels of microorganisms and antibiotic-resistance factors generating a diagnostic report (optionally with quantification of each microorganism or antibiotic-resistance factor) and an approach (Level II) that utilizes universal or semi-universal primers to amplify conserved genes at a general or specific taxonomic level that are tagged specimen specifically using a genetic or chemical marker that is specific to the specimen from which it was derived, then sequencing the amplified products with highly-parallel, high-throughput technology to provide comprehensive sequences of the microbial population in the specimen followed by analysis of this sequence information and specific targeted information from Level I and/or Level II to generate a comprehensive analysis, interpretation, and/or diagnostic report. | 2012-05-24 |
20120129795 | ANTIVIRAL COMPOUNDS - Herein are disclosed novel compounds according to Formula (I) and aggregates comprising such compounds. These aggregates are useful to treat and prevent ocular infections caused by a vims, which virus binds to terminal sialic residues present on the cell surface of the cell to be infected by the virus. | 2012-05-24 |
20120129796 | PEST CONTROLLING COMPOSITION - A pest controlling composition comprising spinetoram and a cyclic keto-enol compound having an acetyl CoA carboxylase-inhibiting activity as active ingredients. | 2012-05-24 |
20120129797 | BIODEGRADABLE STEALTH POLYMERIC PARTICLES FABRICATED USING THE MACROMONOMER APPROACH BY FREE RADICAL DISPERSION POLYMERIZATION - The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-lactate) that is crosslinked by at least one hydrolysable monmer. Another embodiment of the present invention is a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent. Another embodiment of the present invention is a polymer particle comprising, a crosslinked copolymer comprises structures represented by Formulas (I), (II), and (III), where Formulas (I), (II) and (III) are defined in the specification. Yet other embodiments of the present invention include a method of preparing a methacrylate terminated macromonomer, a method of preparing a crosslinking agent, and a method of preparing a therapeutic agent loaded nanosphere by dispersion polymerization. | 2012-05-24 |
20120129798 | STEALTH POLYMERIC PARTICLES FOR DELIVERY OF BIOACTIVE OR DIAGNOSTIC AGENTS - The present invention is directed to a crosslinked or non-crosslinked polymer particle, wherein the crosslinked polymer particle comprises a copolymer of poly(alklyene glycol-graft-acrylate) that is crosslinked by at least one hydrolysable monomer or crosslinking agent. The present invention is also directed to a polymer particle comprising a crosslinked polymer particle that is a product of starting materials comprising (a) a hydrophilic monomer, (b) a hydrophobic monomer, and (c) a hydrolysable crosslinking agent (the crosslinking agent may be absent in the case of non-crosslinked particles). The present invention is still further directed to a polymer particle comprising a crosslinked copolymer, where the crosslinked copolymer includes structures represented by Formulas (I), (II), and (III), as defined in the specification. Other embodiments of the present invention also include methods of manufacturing polymer particles. | 2012-05-24 |
20120129799 | STABLE COMPOSITION OF READY-TO-USE GEMCITABINE INJECTION - The present invention relates to non aqueous pharmaceutical preparations containing gemcitabine or its pharmaceutically, acceptable salts in the form of ready-to-use solutions wherein the concentration of Gemcitabine is in the range of about 16 mg/ml to about 200 mg/ml and a pH of about 3.5 to 10.0. Further, a method for the preparation of non-aqueous Gemcitabine solution of the present invention is also disclosed. | 2012-05-24 |
20120129800 | Agent For Preventing And Treating Pityriasis Versicolor - The present invention concerns an agent for prevention and treatment of pityriasis. | 2012-05-24 |
20120129801 | BLOOD PARASITICIDE - This application relates to compositions and methods of treating tick-born parasitic diseases in livestock with the compositions. The compositions include imidocarb dipropionate, cyanocobalamin vitamin B12, and pharmaceutically acceptable carriers. | 2012-05-24 |
20120129802 | PROCESS FOR THE PRODUCTION OF ULTRAPURE GALACTO-OLIGOSACCHARIDES - The present invention describes a process for preparing ultrapure (≧95%) galacto-oligosaccharides (GOS), starting from GOS at lower purities by using sequential microbiological purifications involving | 2012-05-24 |
20120129803 | COMPOSITION CONTAINING CHITOOLIGOSACCHARIDE FOR RECOVERING FROM FATIGUE - Disclosed is an anti-fatigue composition containing chitooligosaccharide as an active ingredient. The composition exhibits a fatigue recovery effect, and thus can be widely used in the health food or medical field. | 2012-05-24 |
20120129804 | METHODS OF REDUCING ABSORPTION OF TRANS FATTY ACIDS USING WATER-INSOLUBLE CELLULOSE DERIVATIVES - Provided are food products comprising at least 0.5 g of trans fatty acid per serving and one or more water-insoluble cellulose derivatives in an amount sufficient to reduce absorption of the trans fatty acid by a mammal consuming the food product, methods of ameliorating the harmful effects of trans fatty acids on a mammal that has consumed trans fatty acids, and methods of reducing the amount of trans fatty acids capable of being absorbed by a mammal ingesting a trans fatty acid containing food product. | 2012-05-24 |
20120129805 | BARLEY AND USES THEREOF - The invention provides barley gain comprising a reduced level or activity of starch synthase IIa protein and a starch content of at least 41% (w/w) and methods of producing, identifying and using same. The grain may comprise an amylase content of at least 50%, a β-glucan content of 5-9% (w/w) or greater than 9% (w/w), and/or a fructan content of 3-11% (w/w). The fructan may comprise a degree of polymerization from about 3 to about 12. For example, the plant and grain comprises a sex6-292 allele and/or an amo1 mutation. A food or beverage product, and methods of producing a food or beverage product, comprising obtaining or producing the subject grain and processing the grain to produce the product. Also contemplated are methods of improving one or more indicators of health in a mammal comprising administering a composition comprising the subject barley grain or a product comprising same. | 2012-05-24 |
20120129806 | ARGINASE INHIBITORS AS THERAPEUTICS - Compounds according to Formula I are potent inhibitors of Arginase I and II activity: | 2012-05-24 |
20120129807 | METHODS OF TREATMENT, IMPROVEMENT AND PREVENTION USING HALOARYL SUBSTITUTED AMINOPURINES - Provided herein are Aminopurine Compounds having the following structure: | 2012-05-24 |
20120129808 | BLOOD COAGULATION REACTION INHIBITOR - The present invention is a blood coagulation reaction inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The present invention is also a thrombin generation inhibitor comprising phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. The blood coagulation reaction inhibitor and the thrombin generation inhibitor of the present invention are useful as an antithrombotic agent, a clinical laboratory test reagent for the blood coagulation-fibrinolysis system, and the like. | 2012-05-24 |
20120129809 | LUNG CANCER TREATMENT - The invention provides a method for treating NSCLC, especially in cases of KRAS mutation, involving the administration of deforolimus. | 2012-05-24 |
20120129810 | COMBINATION ANTINEOPLASTIC THERAPY - The present invention is directed to methods of using a sirolimus drug and chloroquine or a quinoline derivative in combination. Methods of use are also described. | 2012-05-24 |
20120129811 | TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION - This invention relates to tricycle I and its therapeutic and prophylactic uses, wherein the variables C | 2012-05-24 |
20120129812 | NOVEL THYROID HORMONE BETA RECEPTOR AGONIST - Provided is a heterocyclic derivative showing a thyroid hormone β receptor agonist action, which is effective for the prophylaxis or treatment of the diseases relating to the action. A compound represented by the formula [I]: | 2012-05-24 |
20120129813 | NOVEL COMPOUNDS AS RECEPTOR MODULATORS WITH THERAPEUTIC UTILITY - The present invention relates to novel derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2012-05-24 |
20120129814 | NOVEL PHOSPHONIC ACIDS AS S1P RECEPTOR MODULATORS - The present invention relates to novel phosphonic acids derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors. | 2012-05-24 |
20120129815 | FUNGICIDAL COMPOSITION - A fungicidal composition comprising tolclofos-methyl, polyoxyethylene polyarylphenol phosphate, polyoxylethylene polyoxypropylene block copolymer, polyoxyethylene fatty alcohol ether and water has good stability of the formulation at high temperature. | 2012-05-24 |